Agree. We have waited long enough. We need FDA approval soon and a buyout.
I wonder if Hall would put a press out on this
We want FDA clearance !!!!!!!! NOW!!!!! PLEASE!!!!!!!
Sentiment: Strong Buy
Heart failure and galectin 3
Gabriela Suarez1, Gary Meyerrose2
1Department of Internal Medicine, 2Department of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
Correspondence to: Gary Meyerrose. Professor, Department of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Email: email@example.com.
Abstract: Innovations in medical diagnosis and treatment have led to prolongation of life of patients. Increasing the life expectancy of cardiac patients and thereby increasing the prevalence of heart failure (HF). Currently more than one million hospital admissions per year are due to HF and it has been estimated that the cost is approximately $39 billion annually in the U.S. There are two pathophysiologic myocardial mechanisms that cause HF: systolic dysfunction and diastolic dysfunction. Normal cardiac aging is characterized by morphological and structural changes that increase cardiomyocyte size, increased number of apoptosis with decreased number in myocytes, increased collagen deposition, and functional changes at cellular level. All these factors contribute to fibrotic remodeling that leads to LV diastolic stiffness, which ultimately leads to impaired diastolic function. At the same time it has been shown that galectin-3, a soluble β-galactoside-binding protein secreted by activated macrophages, promotes cardiac fibroblast proliferation, collagen deposition, and ventricular dysfunction. In this paper we review the prognostic value of galectin-3 as an independent predictor of mortality in patients with moderate to advanced chronic HF (CHF).
Keywords: Galectin 3; systolic heart failure (HF); diastolic HF
Submitted Sep 09, 2014. Accepted for publication Sep 15, 2014.
There is more google for the rest
also, they are not paying some board members to save cash for other operational menas no mention of abbott thoughts
WARRANTS TO BUY OR OPTION GRANTS TO BUY, NEVER AN OUTRIGHT GRANT OF STOCK.
This little bit of news gives you food for thought, You'll find out whats really going on in the 10Q in early November.
agree.....sets up a buyout scenario and these 2 guys ride off in the sunset and Abbott takes over and adds this product to their platform of income producing products......
this would not have happened if they thought for a second FDA was not going to approve.....I see today and the news as a huge plus and indicator of good to come for longs here.
I agree with you on those points Jess, My worry here is that they must continue paying on the GE Loan, God forbid they default on that loan, That would be the end.
it is simply a very good business decision by BG management......why pay non-employee Directors at this point in time, they cant add anything to the company and should not be paid for doing nothing....it is all about waiting for FDA clearance.....also, Abbott probably feels those directors dont need to be paid at this point....some say Abbottt will buy BGMD soon, and when and if they do, some of these business decisions will have already been made, thus making Abbott "not the bad guy" post buyout......